MECHANISMS OF RESISTANCE TO MENIN INHIBITOR THERAPY AND ACUTE MYELOID LEUKAEMIA
With
Dr Rithin Nedumannil,
Consultant Haematologist and PhD Candidate,
Peter MacCallum Cancer Centre,
Austin Health,
Eastern Health,
Royal Melbourne Hospital
Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | June 2025
Dr Rithin Nedumannil (MBBS, MPH, FRACP, FRCPA) is a PhD candidate at the University of Melbourne, undertaking his doctoral studies in collaboration with the Cambridge Stem Cell Institute (Cambridge, UK) and the Peter MacCallum Cancer Centre (Melbourne, Australia). He is a clinical haematologist and haematopathologist with current appointments at Peter MacCallum Cancer Centre, the Royal Melbourne Hospital, Austin Health and Northern Health.
After completing his medical degree at the University of Adelaide, Dr Nedumannil undertook advanced training in clinical and laboratory haematology across Melbourne’s major tertiary centres. He was awarded dual fellowships (FRACP and FRCPA) and went on to complete a subspecialty fellowship in Acute Leukaemia and Myelodysplastic Syndromes at Peter MacCallum Cancer Centre and the Royal Melbourne Hospital in 2024. He also holds a Master of Public Health from the University of New South Wales.
His interest in translational leukaemia research has been shaped by extensive clinical experience and academic work focusing on measurable residual disease, novel fusion genes and treatment resistance in acute leukaemias. His PhD will explore resistance mechanisms to menin inhibitors in acute myeloid leukaemia (AML) using genome-scale technologies including CRISPR screening, RNA sequencing and epigenomic profiling. His research will be conducted over two years at the Cambridge Stem Cell Institute and one year at Peter MacCallum Cancer Centre.
For this work, Dr Nedumannil has been awarded the 2025 Haematology Society of Australia and New Zealand and Leukaemia Foundation New Investigator PhD Scholarship, supporting his goal of translating molecular insights into improved therapeutic strategies for high-risk AML.
Source: Supplied
https://orcid.org/0000-0002-0883-3942
-
Newborn screening for congenital hypothyroidism
Assoc Prof Jack is passionate about the health and wellbeing of children and adolescents, with diverse research areas including the impacts of family friendly workplace initiatives, screening and management of thyroid disorders in infants and children. She supports her First Nations colleagues on Indigenous-led research projects funded by the Medical Research Future Fund, aiming to improve the social and emotional wellbeing of First Nations Children. Through her clinical and academic roles, Assoc Prof Jack hopes to make a positive difference to the health and well-being of children and their families.
-
Good and bad extracellular vesicles in health and disease
Associate Professor Joy Wolfram has joint appointments in the School of Chemical Engineering and the Australian Institute for Bioengineering and Nanotechnology at The University of Queensland, and through her work at the AIBN, she aims to develop a new paradigm of therapeutics (using nanotechnology and cell products) to treat life-threatening diseases that are major causes of death globally, including cardiovascular disease, kidney disease, and breast cancer.
-
Podiatric Research In Children, the workforce and the LGBTQIA+ community
Professor Williams holds the role of Deputy Head of School, School of Primary and Allied Health Care, and course coordinator of the Doctor of Podiatric Medicine degree. She is a podiatrist, and has held professional roles in community health, acute and subacute services in child health care teams, research leadership and professional governance.
